Online citations, reference lists, and bibliographies.
← Back to Search

Promising Immunotherapy: Highlighting Cytokine‐induced Killer Cells

S. Shirjang, N. Alizadeh, B. Mansoori, A. Mahmoodpoor, H. Kafil, M. Hojjat-Farsangi, M. Yousefi
Published 2019 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
For many years, cancer therapy has appeared to be a challenging issue for researchers and physicians. By the introduction of novel methods in immunotherapy, the prospect of cancer therapy even more explained than before. Cytokine‐induced killer (CIK) cell‐based immunotherapy demonstrated to have potentiality in improving clinical outcomes and relieving major side effects of standard treatment options. In addition, given the distinctive features such as high safety, low toxicity effects on healthy cells, numerous clinical trials conducted on CIK cells. Due to the shortcomings that observed in CIK cell immunotherapy alone, arising a tendency to make modifications (combined modality therapy or combination therapy) including the addition of various types of cytokines, genetic engineering, combination with immune checkpoints, and so on. In this review, we have tried to bring forth the latest immunotherapy methods and their overview. We have discussed the combination therapies with CIK cells and the conducted clinical trials. This helps the future studies to use integrated therapies with CIK cells as a promising treatment of many types of cancers.
This paper references
10.1038/sj.bmt.1704086
IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial
L. Burns (2003)
10.1038/mt.2014.164
Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia.
Q. Wang (2015)
10.1124/pr.114.009456
Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy
S. Anguille (2015)
10.1097/CJI.0b013e31815a121b
Minimally Invasive Treatment Combined With Cytokine-induced Killer Cells Therapy Lower the Short-term Recurrence Rates of Hepatocellular Carcinomas
D. Weng (2008)
10.1007/s13277-013-1265-2
The CIK cells stimulated with combination of IL-2 and IL-15 provide an improved cytotoxic capacity against human lung adenocarcinoma
C. Wei (2013)
10.1016/J.EJCA.2018.01.057
Enhancing Cytokine-Induced Killer (CIK) cell activity with Her2-specific Fc-engineered antibodies and antibody derivatives
Elisa Cappuzzello (2018)
10.1186/s40425-016-0193-2
Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients
M. Nishino (2016)
10.1016/j.semcancer.2015.03.004
Immune evasion in cancer: Mechanistic basis and therapeutic strategies.
D. Vinay (2015)
Biological activity of DC-CIK cells and its effect against leukemia cells in vitro.
Xu-Cang Wei (2008)
10.1056/NEJMoa1305133
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
O. Hamid (2013)
10.1158/1078-0432.CCR-11-0116
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
S. Rosenberg (2011)
10.1016/j.jgo.2016.05.007
The development of immunotherapy in older adults: New treatments, new toxicities?
C. Hélissey (2016)
[Clinical study of autologous cytokine induced killer cell infusion treating for elderly patients with myelodysplastic syndrome].
Y. Liu (2011)
10.1007/s12013-011-9273-6
Clinical Study of Autologous Cytokine-Induced Killer Cells for the Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma
X. Lu (2011)
10.1016/J.YMTHE.2005.04.016
A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells.
M. Pule (2005)
10.1200/JCO.1995.13.8.1939
Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
P. Goedegebuure (1995)
10.1517/14740338.2013.795944
Cancer immunotherapies, their safety and toxicity
G. Alatrash (2013)
A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Digestive and liver disease
D Hui (2009)
Cancer immunology for the clinician.
L. Weiner (2015)
10.1111/1348-0421.12408
Synergistic antitumor effect of a human papillomavirus DNA vaccine harboring E6E7 fusion gene and vascular endothelial growth factor receptor 2 gene
J. Gao (2016)
10.1016/j.intimp.2010.12.014
Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies.
Q. Niu (2011)
10.1158/1940-6207.CAPR-14-0178
Cancer Immunoprevention—The Next Frontier
M.-A. D. Smit (2014)
10.1200/JCO.2014.56.2025
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
J. Kochenderfer (2015)
10.1016/j.molimm.2012.03.023
Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor.
Megan E Prosser (2012)
10.1126/scitranslmed.3005930
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
R. Brentjens (2013)
10.1084/JEM.155.6.1823
Lymphokine-activated killer cell phenomenon. Lysis of natural killer- resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes
E. Grimm (1982)
10.1016/j.leukres.2011.05.005
Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one?
S. Thanendrarajan (2011)
10.1038/nrc3239
The blockade of immune checkpoints in cancer immunotherapy
D. Pardoll (2012)
10.1038/sj.gt.3300560
Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene
S. Finke (1998)
10.2967/jnumed.110.075101
Renal Toxicity of Radiolabeled Peptides and Antibody Fragments: Mechanisms, Impact on Radionuclide Therapy, and Strategies for Prevention
E. Vegt (2010)
10.1016/j.clinthera.2016.03.026
Current Challenges in Cancer Treatment.
J. Zugazagoitia (2016)
10.1155/2014/525913
Cell Transfer Therapy for Cancer: Past, Present, and Future
X. Qian (2014)
10.1097/00002371-200409000-00009
Intracavitary Placement of Autologous Lymphokine-Activated Killer (LAK) Cells after Resection of Recurrent Glioblastoma
R. Dillman (2004)
10.1182/blood-2011-01-329508
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.
A. Curti (2011)
10.1038/bmt.2012.162
Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers
M. Stern (2013)
10.1182/blood-2011-10-384388
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
J. Kochenderfer (2012)
10.1016/S0140-6736(14)61403-3
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
D. Lee (2015)
10.1056/NEJMoa1103849
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.
D. Porter (2011)
10.1182/blood-2010-06-290858
Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies.
A. Pievani (2011)
10.21037/cco.2017.02.07
Advances in evidence-based cancer adoptive cell therapy.
Chunlei Ge (2017)
10.1007/s13277-015-4732-0
Downregulation of CD73 in 4T1 breast cancer cells through siRNA-loaded chitosan-lactate nanoparticles
Farhad Jadidi-Niaragh (2015)
10.4049/jimmunol.179.9.5845
High-Affinity TCRs Generated by Phage Display Provide CD4+ T Cells with the Ability to Recognize and Kill Tumor Cell Lines1
Y. Zhao (2007)
10.1007/s00262-016-1815-8
Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts
Su Li Poh (2016)
10.1158/1078-0432.CCR-13-0895
Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
M. Nishino (2013)
10.1056/NEJMoa1407222
Chimeric antigen receptor T cells for sustained remissions in leukemia.
Shannon L Maude (2014)
10.4049/jimmunol.1500447
NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype
E. Ames (2015)
10.18632/oncotarget.5463
A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma
S. Jiang (2015)
10.3892/or.2015.4233
Anti-CD3 x EGFR bispecific antibody redirects cytokine-induced killer cells to glioblastoma in vitro and in vivo.
P. Ma (2015)
10.1016/j.biopha.2017.01.120
The role of IL17B-IL17RB signaling pathway in breast cancer.
V. Alinejad (2017)
10.3892/OL.2016.4839
Influence of autologous dendritic cells on cytokine-induced killer cell proliferation, cell phenotype and antitumor activity in vitro.
Jingsong Cao (2016)
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma.
Darryl A. Oble (2009)
10.1016/J.EXPHEM.2006.05.004
Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy.
V. Marin (2006)
[Dendritic cells reduce the number and function of CD4+CD25+ cells in cytokine-induced killer cells].
H. Li (2005)
10.1074/jbc.M807761200
STAT3-Stathmin Interactions Control Microtubule Dynamics in Migrating T-cells*
N. Verma (2009)
Treatment of rectal cancer by transanal endoscopic microsurgery: review of the literature.
G. Lezoche (2013)
[The cytotoxicity of CIK/NK cells stimulated by K562-DC fusion vaccines in NOD/SCID mice model for human erythroleukemia].
Y. Li (2008)
[Multimodal treatment for acute antibody-mediated renal transplant rejection: successful rescue therapy with combined plasmapheresis, photopheresis and intravenous immunoglobulin].
Q. Lai (2012)
10.1016/j.exphem.2014.08.005
Direct involvement of CD56 in cytokine-induced killer-mediated lysis of CD56+ hematopoietic target cells.
R. Valgardsdottir (2014)
[CD4 TIL (Tumor Infiltrating Lymphocytes) induce complete response in patients treated with IL-2 (Interleukin-2). Preliminary study].
N. Thiounn (1994)
Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
R. Freedman (2000)
10.1002/cbin.10553
Interleukin‐15‐transferred cytokine‐induced killer cells elevated anti‐tumor activity in a gastric tumor‐bearing nude mice model
Z. Peng (2016)
10.1016/j.imlet.2017.01.014
2003-2013, a valuable study: Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in stage IV breast cancer.
M. Lin (2017)
10.1016/J.EXPHEM.2007.05.018
Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-zeta activating signal.
V. Marin (2007)
10.4161/23723556.2014.976507
Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma
Jiang Li (2015)
10.2147/OTT.S139986
Comparison of autogeneic and allogeneic natural killer cells immunotherapy on the clinical outcome of recurrent breast cancer
Shuzhen Liang (2017)
10.1007/s00262-014-1575-2
A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma
I. Poschke (2014)
10.1158/1078-0432.CCR-13-0143
CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
P. Ott (2013)
10.1016/j.exphem.2009.01.010
Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes.
M. Franceschetti (2009)
10.3748/WJG.V8.I3.464
Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo.
F. Wang (2002)
10.1006/CYTO.2000.0733
Modulation of cell surface markers on NK-like T lymphocytes by using IL-2, IL-7 or IL-12 in vitro stimulation.
B. Zoll (2000)
10.1046/j.1365-2141.2002.03247.x
Generation of cytokine‐induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous 
and allogeneic leukaemic blasts
Y. C. Linn (2002)
10.1016/S1470-2045(17)30251-6
Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.
S. Chandran (2017)
10.1056/NEJMoa1003466
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
10.1158/1078-0432.CCR-13-0061
Effective Activity of Cytokine-Induced Killer Cells against Autologous Metastatic Melanoma Including Cells with Stemness Features
L. Gammaitoni (2013)
10.1038/bjc.1972.21
Eighty years of immunotherapy: a review of immunological methods used for the treatment of human cancer.
G. Currie (1972)
10.1158/1078-0432.CCR-13-0380
Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies
M. Besser (2013)
10.1002/pros.23214
Phase I Trial of Anti‐PSMA Designer CAR‐T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2‐T Cell Pharmacodynamics as a Determinant of Clinical Response
R. Junghans (2016)
10.1038/320232A0
Transfer of specificity by murine α and β T-cell receptor genes
Z. Dembić (1986)
10.1007/s00432-014-1864-3
Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC)
L. Schmeel (2014)
10.1111/j.1537-2995.2012.03764.x
Autologous stem cell transplant recipients tolerate haploidentical related‐donor natural killer cell–enriched infusions
H. Klingemann (2013)
10.1056/NEJMoa1501824
Pembrolizumab for the treatment of non-small-cell lung cancer.
E. Garon (2015)
10.1038/nrc3565
Gene-engineered T cells for cancer therapy
M. Kershaw (2013)
10.1016/S1470-2045(17)30607-1
De-novo and acquired resistance to immune checkpoint targeting.
N. Syn (2017)
10.1200/JCO.2014.58.0225
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.
N. Ahmed (2015)
10.1038/nm.2700
Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer
E. Provasi (2012)
10.1016/j.jaut.2017.06.008
CIK as therapeutic agents against tumors.
M. Introna (2017)
10.1097/CJI.0000000000000001
IL-15 Improves the Cytotoxicity of Cytokine-induced Killer Cells Against Leukemia Cells by Upregulating CD3+CD56+ Cells and Downregulating Regulatory T Cells As Well As IL-35
Q. Tao (2013)
a valuable study: autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in stage IV breast cancer
M Lin (2003)
10.1002/IJC.1506.ABS
Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases.
D. Berd (2001)
10.3389/fimmu.2015.00633
Rapid Response of Advanced Squamous Non-Small Cell Lung Cancer with Thrombocytopenia after First-Line Treatment with Pembrolizumab Plus Autologous Cytokine-Induced Killer Cells
Z. Hui (2015)
10.1073/pnas.1010568107
CD4 and CD8 binding to MHC molecules primarily acts to enhance Lck delivery
Maxim N. Artyomov (2010)
10.3390/ijms150814632
Adoptive Immunotherapy Strategies with Cytokine-Induced Killer (CIK) Cells in the Treatment of Hematological Malignancies
F. Schmeel (2014)
10.1016/S1074-7613(02)00333-3
The role of the NKG2D immunoreceptor in immune cell activation and natural killing.
A. Jamieson (2002)
10.1038/mt.2010.272
T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis.
M. Parkhurst (2011)
10.1126/science.aaa8172
The future of immune checkpoint therapy
P. Sharma (2015)
10.1182/blood-2010-07-294520
Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.
C. Lamers (2011)
10.1172/JCI46110
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.
B. Savoldo (2011)
10.4161/mabs.27022
Site-specific antibody drug conjugates for cancer therapy
S. Panowski (2014)
10.1056/NEJMoa1504627
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
J. Brahmer (2015)
10.1016/j.dld.2008.04.007
A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma.
Dong Hui (2009)
Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes
E A Grimm (1982)
10.1158/1078-0432.CCR-06-1183
A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
M. Kershaw (2006)
10.1016/j.biopha.2015.08.009
MicroRNA-induced drug resistance in gastric cancer.
Rashedeh Dehghanzadeh (2015)
10.1006/rwei.1999.0416
Lymphokine-Activated Killer (LAK) Cells
R. Herberman (1998)
10.1172/JCI43437
MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors.
M. Leisegang (2010)
10.1056/NEJMoa1610497
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.
C. Brown (2016)
10.1016/j.clim.2013.07.006
Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo.
Jian-hua Huang (2013)
10.18632/oncotarget.7243
Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer
C. Dai (2016)
10.1073/pnas.0813101106
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
C. Carpenito (2009)
10.1056/NEJMoa1001294
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
P. Kantoff (2010)
10.1155/2012/238924
Improved Activation toward Primary Colorectal Cancer Cells by Antigen-Specific Targeting Autologous Cytokine-Induced Killer Cells
C. Schlimper (2012)
10.1126/scitranslmed.3008226
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
M. Davila (2014)
10.3892/ol.2013.1281
Cytotoxicity of cytokine-induced killer cells targeted by a bispecific antibody to gastric cancer cells
L. Zhang (2013)
10.1126/SCIENCE.1129003
Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes
R. Morgan (2006)
10.3389/fimmu.2017.00774
Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy
X. Gao (2017)
10.3109/10428190309178764
Cytokine-induced Killer Cells: NK-like T Cells with Cytotolytic Specificity against Leukemia
Y. C. Linn (2003)
10.1080/2162402X.2017.1423167
CD44v6 as innovative sarcoma target for CAR-redirected CIK cells
V. Leuci (2018)
10.1182/BLOOD-2004-07-2974
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.
J. Miller (2005)
10.1158/1078-0432.CCR-14-1421
Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases
S. Katz (2015)
10.1007/s11912-012-0257-5
Tumor-Infiltrating Lymphocytes in Melanoma
S. Lee (2012)
10.1002/1097-0142(19850315)55:6<1327::AID-CNCR2820550628>3.0.CO;2-O
Lymphokine‐activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer
A. Rayner (1985)
10.1038/mt.2009.210
Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.
X. Zhong (2010)
Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells.
Jingting Jiang (2006)
10.1038/nature06175
Taking dendritic cells into medicine
R. Steinman (2007)
Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer.
Changping Wu (2008)
Alloreactivity and anti‐tumor activity segregate within two distinct subsets 8878 | SHIRJANG ET AL. of cytokine‐induced killer (CIK) cells: implications for their infusion across major HLA barriers
D Sangiolo (2008)
10.1158/2326-6066.CIR-13-0006
T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
M. Maus (2013)
Tumor necrosis factor: how to improve the antitumor activity and decrease accompanying side effects for therapeutic application.
K. Haranaka (1988)
10.1084/JEM.174.1.139
Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity
I. Schmidt-Wolf (1991)
10.3892/etm.2015.2264
Anti-CD20 antibody induces the improvement of cytokine-induced killer cell activity via the STAT and MAPK/ERK signaling pathways
Q. Deng (2015)
10.1111/j.1365-2567.2008.02910.x
Characterization of the recognition and functional heterogeneity exhibited by cytokine‐induced killer cell subsets against acute myeloid leukaemia target cell
Y. C. Linn (2009)
10.2217/imt-2016-0112
Adoptive cell therapy: past, present and future.
J. Cohen (2017)
10.1016/J.BBMT.2004.11.019
A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma.
T. Leemhuis (2005)
10.3109/14653249.2011.613931
The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells.
E. Rettinger (2012)
10.1200/JCO.2013.53.0105
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
S. Topalian (2014)
Prospects in Adoptive Cell Transfer Therapy for Cancer
Yanmin Li (2014)
10.1007/BF02967383
New guidelines to evaluate the response to treatment in solid tumors
P. Therasse (2000)
10.1016/J.YONC.2012.07.009
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
A. Tsao (2012)
10.4103/0973-1482.113348
Cancer patients with cardiac pacemakers needing radiation treatment: a systematic review.
A. Munshi (2013)
10.1016/j.exphem.2008.04.010
Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma.
A. Barber (2008)
10.1182/blood-2011-09-380519
Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models.
Jae Hun Shin (2012)
10.3748/WJG.V10.I8.1146
Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma.
Ming Shi (2004)
10.3390/cancers3043856
Cytokines in Cancer Immunotherapy
S. Lee (2011)
10.1002/ijc.30217
Chimeric antigen receptor‐engineered cytokine‐induced killer cells overcome treatment resistance of pre‐B‐cell acute lymphoblastic leukemia and enhance survival
Sarah Oelsner (2016)
10.1007/s00262-007-0333-0
Cytokine-induced killer cells targeted by the novel bispecific antibody CD19xCD5 (HD37xT5.16) efficiently lyse B-lymphoma cells
Freddy Tita-Nwa (2007)
10.1016/j.bbmt.2016.04.009
Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
D. Lee (2016)
10.4049/jimmunol.172.1.104
Activation of Resting Human Primary T Cells with Chimeric Receptors: Costimulation from CD28, Inducible Costimulator, CD134, and CD137 in Series with Signals from the TCRζ Chain
H. Finney (2004)
10.1016/0169-5002(95)00478-J
Adjuvant immunotherapy with interleukin 2 and lymphokine-activated killer cells after noncurative resection of primary lung cancer.
H. Kimura (1995)
10.1371/journal.pone.0044802
Combined Therapy with Cytokine-Induced Killer Cells and Oncolytic Adenovirus Expressing IL-12 Induce Enhanced Antitumor Activity in Liver Tumor Model
Z. Yang (2012)
10.1002/1097-0142(19950901)76:5<824::AID-CNCR2820760517>3.0.CO;2-N
Phase iii randomized trial of interleukin‐2 with or without lymphokine‐activated killer cells in the treatment of patients with advanced renal cell carcinoma
T. M. Law (1995)
10.1126/SCIENCE.6332379
Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.
J. Mulé (1984)
10.1002/hon.886
Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial
P. Olioso (2009)
10.1038/mt.2013.17
Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.
C. Lamers (2013)
Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma.
R. Royal (1996)
10.1002/pbc.26147
Cytotoxic potential of IL‐15‐activated cytokine‐induced killer cells against human neuroblastoma cells
C. Cappel (2016)
10.1016/0163-7258(93)90037-E
Tumor necrosis factor activities and cancer therapy--a perspective.
R. S. Sidhu (1993)
10.1038/mt.2009.83
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.
Michael C Milone (2009)
10.1146/ANNUREV.IMMUNOL.14.1.233
CD28/B7 system of T cell costimulation.
D. Lenschow (1996)
10.1186/s13045-015-0227-0
Bispecific antibodies and their applications
Gaowei Fan (2015)
10.3892/ol.2018.7954
Novel TLR7 agonist stimulates activity of CIK/NK immunological effector cells to enhance antitumor cytotoxicity.
D. Gao (2018)
10.1152/ajpgi.90689.2008
Role of the perforin/granzyme cell death pathway in D-Gal/LPS-induced inflammatory liver injury.
A. Kuhla (2009)
10.1038/77793
Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages
A. Diefenbach (2000)
10.1097/CJI.0b013e318255ada3
Interleukin-6 Inhibits Regulatory T Cells and Improves the Proliferation and Cytotoxic Activity of Cytokine-induced Killer Cells
Guohe Lin (2012)
10.1038/sj.bmt.1705503
Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation
M. Introna (2006)
10.1182/blood-2009-02-205278
Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).
I. Borrello (2009)
10.1080/01635581.2013.770043
Multitargeting and Antimetastatic Potentials of Silibinin in Human HepG-2 and PLC/PRF/5 Hepatoma Cells
R. Ghasemi (2013)
10.1038/sj.bjc.6690800
Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma
I. Schmidt-Wolf (1999)
10.1088/0957-4484/21/15/155103
Development of pH sensitive 2-(diisopropylamino)ethyl methacrylate based nanoparticles for photodynamic therapy.
C. Peng (2010)
10.1097/00002371-199605000-00006
Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced hepatocellular carcinoma: comparison between LAK cell and CTL therapy.
I. Haruta (1996)
10.1182/blood-2013-08-519413
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.
J. Kochenderfer (2013)
10.1158/1078-0432.CCR-07-0674
Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts
R. Brentjens (2007)
[The proliferation profile in vitro and anti-tumor effects of dendritic cells co-culturing with CIK cells].
S. Zhang (2003)
10.1046/j.1440-1711.1999.00837.x
Cell death induced by the Fas/Fas ligand pathway and its role in pathology
P. Waring (1999)
10.3324/haematol.2010.026310
Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors
V. Marin (2010)
10.4049/jimmunol.171.6.3287
High Efficiency TCR Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the Recognition of Autologous Melanoma Antigens
R. Morgan (2003)
10.1006/CIMM.1996.0094
Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells.
I. Schmidt-Wolf (1996)
10.1126/scitranslmed.3010274
On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation
A. Lesokhin (2015)
10.1158/1078-0432.CCR-07-4910
Second-Generation Anti–Carcinoembryonic Antigen Designer T Cells Resist Activation-Induced Cell Death, Proliferate on Tumor Contact, Secrete Cytokines, and Exhibit Superior Antitumor Activity In vivo: A Preclinical Evaluation
P. Emtage (2008)
10.1007/s00262-004-0554-4
Dendritic cells reduce number and function of CD4+CD25+ cells in cytokine-induced killer cells derived from patients with pancreatic carcinoma
J. Schmidt (2004)
10.3390/ijms17071056
Increased Efficacy of Brentuximab Vedotin (SGN-35) in Combination with Cytokine-Induced Killer Cells in Lymphoma
Laura Esser (2016)
10.1016/j.bbmt.2011.05.012
Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation.
G. Laport (2011)
10.1016/S0167-5699(97)84664-6
Cancer vaccines based on the identification of genes encoding cancer regression antigens.
S. Rosenberg (1997)
10.1200/JCO.2009.24.4590
NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.
J. Rubnitz (2010)
10.1016/j.biopha.2016.09.082
Role of oral microbiome on oral cancers, a review.
P. Gholizadeh (2016)
10.1084/JEM.173.4.1017
DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells
J. Houchins (1991)
10.1146/annurev.immunol.26.021607.090331
PD-1 and its ligands in tolerance and immunity.
M. Keir (2008)
10.1006/GENO.1997.4721
A 2-Mb YAC contig and physical map of the natural killer gene complex on mouse chromosome 6.
M. Brown (1997)
10.3109/14653249.2011.649185
Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis.
Y. Ma (2012)
10.1097/00007890-199705150-00002
Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients.
M. Nalesnik (1997)
10.1111/imr.12328
Genetics, genomics, and evolutionary biology of NKG2D ligands
R. Carapito (2015)
A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.
P. Lu (1994)
10.1016/j.imlet.2017.07.015
Nanoparticles and targeted drug delivery in cancer therapy.
B. Bahrami (2017)
10.1093/intimm/dxn042
Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers.
D. Sangiolo (2008)
10.18632/oncotarget.9871
Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients
L. Zhang (2016)
10.1038/nm.2197
Transgenic mice with a diverse human T cell antigen receptor repertoire
Liang-ping Li (2010)
Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells.
I. Schmidt-Wolf (1993)
10.1016/0022-1759(94)90084-1
Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy.
R. Freedman (1994)
Imlygic (Talimogene Laherparepvec): First Oncolytic Viral Therapy for the Treatment of Patients with Recurrent Melanoma
Lisa A. Raedler (2016)
10.1016/J.CYTOGFR.2004.11.001
Tumor necrosis factor, cancer and anticancer therapy.
S. Mocellin (2005)
10.1146/ANNUREV.IMMUNOL.22.012703.104803
The three Es of cancer immunoediting.
Gavin P Dunn (2004)
10.1371/journal.pone.0093591
Dendritic Cells Decreased the Concomitant Expanded Tregs and Tregs Related IL-35 in Cytokine-Induced Killer Cells and Increased Their Cytotoxicity against Leukemia Cells
Y. Pan (2014)
10.3109/14653249.2012.694419
A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission.
Y. Linn (2012)
10.1182/BLOOD-2003-06-2125
Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells.
M. Verneris (2004)
10.1097/00002371-200111000-00007
Interactions Between Dendritic Cells and Cytokine-Induced Killer Cells Lead to an Activation of Both Populations
A. Maerten (2001)
10.2174/1389201016666150619114554
Immunotherapy Approaches in Cancer Treatment.
P. Klener (2015)
10.1200/JCO.2015.64.5929
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.
Jennifer N. Brudno (2016)
10.3324/HAEMATOL.11132
Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study.
M. Introna (2007)
10.1038/bmt.2009.304
Generation of donor natural killer cells from CD34+ progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study
S. Yoon (2010)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar